Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proline
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular, Subcutaneous, Topical
01
Overview
Proline is a non-essential alpha-amino acid, meaning the human body can synthesize it. It is a fundamental building block for proteins, particularly collagen, which is the most abundant protein in the body and crucial for the structure and integrity of skin, bones, joints, tendons, ligaments, and blood vessels. Proline plays vital roles in protein synthesis, metabolism, wound healing, and cellular stress responses. It is commonly used in dietary supplements to support collagen production and joint health, and as an ingredient in pharmaceutical formulations like parenteral nutrition solutions. It can also act as a stabilizer in some prescription products.
- Other names
- 脯氨酸L-Proline
02
Targets
AMPAR (AMPA receptor)Glycine receptorKainate-type ionotropic glutamate receptorNMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on Proline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proline.